) The focus of the Carcinogenesis and Chemoprevention Program (C&C) is on the development of basic, clinical and translational studies on cancer causation and prevention. The C&C has been reorganized and renamed since the last review. New members interested in clinical and translational studies have been recruited. The C&C Program now has 14 full and 2 associate investigators representing four departments in the Schools of Medicine and Pharmacy at UCHSC and two additional affiliated institutions (AMC Cancer Research Center and Colorado State University). The C&C Program scientific goals are to develop new approaches to understanding the mechanisms and early pathogenesis of cancer in order to improve the biological basis for predicting the risk of carcinogenesis associated with exposure to exogenous agents and to develop novel intervention strategies for chemoprevention of cancer in humans. During the past five years this internationally recognized group of faculty have provided several key insights into molecular events associated with the development of chemical carcinogenesis and leukemogenesis, identification of genetic polymorphisms that place individuals at increased risk of developing cancer, and the development of antineoplastic and chemoprotective agents, including compounds that are now in clinical trials. The quality and productivity of program members in meeting these goals is also reflected in the level of their grant support and publication record. During this funding period members have published a total of 162 reports in highly respected journals, including 8 in first tier journals (e.g., PNAS, JNCI, Science, etc.). Program members are very well funded, with 36 grants and over $5 million in direct extramural support, including 7 grants of about $1 million in NCI (directs) research funding. This represents an absolute increase of 150% in NCI direct funding and over a 200% increase in direct funding since the last site visit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-15
Application #
6589977
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Salmon, Loïc; Stull, Frederick; Sayle, Sabrina et al. (2018) The Mechanism of HdeA Unfolding and Chaperone Activation. J Mol Biol 430:33-40
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
Tuttle, Kathryn D; Krovi, S Harsha; Zhang, Jingjing et al. (2018) TCR signal strength controls thymic differentiation of iNKT cell subsets. Nat Commun 9:2650
Keysar, Stephen B; Eagles, Justin R; Miller, Bettina et al. (2018) Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. Clin Cancer Res 24:2935-2943
Antonioli, Alexandra H; White, Janice; Crawford, Frances et al. (2018) Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins. J Immunol 200:316-326
Boswell, Zachary K; Rahman, Samiur; Canny, Marella D et al. (2018) A dynamic allosteric pathway underlies Rad50 ABC ATPase function in DNA repair. Sci Rep 8:1639
Steckelberg, Anna-Lena; Akiyama, Benjamin M; Costantino, David A et al. (2018) A folded viral noncoding RNA blocks host cell exoribonucleases through a conformationally dynamic RNA structure. Proc Natl Acad Sci U S A 115:6404-6409
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Graybill, Chiharu; Morgan, Michael J; Levin, Myron J et al. (2018) Varicella-zoster virus inhibits autophagosome-lysosome fusion and the degradation stage of mTOR-mediated autophagic flux. Virology 522:220-227
Kessler, Elizabeth R; Su, Lih-Jen; Gao, Dexiang et al. (2018) Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther 17:1103-1108

Showing the most recent 10 out of 1634 publications